美国食品和药品管理局还没有批准阿瓦斯汀用于眼部治疗，使用它来代替雷珠单抗可能会产生额外的安全风险，尽管这一风险也许很轻微。
The Food and Drug Administration has not approved Avastin for use in the eye, and using it rather than the alternative, Lucentis, might carry an additional, although slight, safety risk.
结果：通过硬化治疗技术，在肠管狭窄区的远端和中间部分注射英夫利昔单抗，全部3名患者的结肠狭窄都得到了扩张。
Results: in all 3 patients, dilation of a colonic stricture was accomplished by injection of infliximab, via the sclerotherapy technique, into the distal and medial portions of the stricture.
免疫抑制剂治疗，如利妥昔单抗，硫唑嘌呤和环磷酰胺，明显减少抗体水平和复发率。
Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.
曲妥珠单抗是一种人源化抗体，用于靶向和阻断her2的功能，而后者是由特异基因编码的一种蛋白，具有致癌潜能。
Trastuzumab is a humanised antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential.
欧洲药品局emea已经限制西妥昔单抗和帕尼单抗在这些患者使用。
EMEA, the European Medicines Agency, has already restricted use of cetuximab and panitumumab to such patients.
结论：我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
Conclusion Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
已报道有关利妥昔单抗的毒性表皮坏死，但毒性表皮坏死和苯达莫司汀的关系尚不确定。
Toxic epidermal necrolysis has been reported for rituximab, but the relationship of toxic epidermal necrolysis to bendamustine has not been determined.
该研究中，302名患者接受吉西他滨合用贝伐单抗，300名患者接受吉西他滨和安慰剂。
The study researchers assigned 302 patients to receive Avastin and Gemzar and assigned an additional 300 patients to receive Gemzar plus placebo.
治疗前先行活组织检查和血浆样本的采集，西妥昔单抗应用之前，CRT之前，即手术的时机。
Biopsies and plasma samples were taken before treatment, after cetuximab but before CRT, and at the time of surgery.
目的观察贝伐单抗与化疗药物联合用于晚期结直肠癌一线治疗的近期疗效和安全性。
OBJECTIVE To evaluate the efficacy and safety of bevacizumab when added to first-line irinotecan-based chemotherapy in patients with metastatic colorectal cancer.
背景在克罗恩病患者中，英夫利西单抗和硫唑嘌呤单药治疗或联合治疗的相对疗效和安全性尚未被了解。
Background the comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.
在2006年6月，数据监测和安全委员会发现加用贝伐单抗并不能使患者受益，于是停止了该研究。
The study was halted prematurely in June 2006 when the Data Monitoring and Safety Board determined that there did not appear to be any benefit to patients in continuing to take bevacizumab.
蛋白组学和微数列用来检测西妥昔单抗的分子有效性并且明确生物标记物对疗效的预测方面的作用。
Proteomics and microarrays were used to monitor the molecular response to cetuximab and to identify profiles and biomarkers to predict treatment efficacy.
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
在第三个治疗周期后，贝伐单抗与显著增多的毒性事件有关系，特别是发热引起的粒细胞减少和肺出血。
After the third treatment cycle, bevacizumab was associated with significantly more toxic events, particularly febrile neutropenia and pulmonary hemorrhage.
例如，委员会使用的关于单克隆抗体西妥昔单抗和帕尼单抗(它们抑制转移性结直肠癌的表皮生长因子受体egfr)的数据。
For example, the Panel used data for the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGF receptor (EGFR) in metastatic colorectal cancer.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。
The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
依法利珠单抗可以很好的被耐受。明显的副作用包括血小板减少，病毒性胃肠炎和停药后仍然出现的湿疹的恶化。
Efalizumab was generally well tolerated. significant side effects included thrombocytopenia viral gastroenteritis and worsening eczema despite drug discontinuation.
目的：评价英利昔单抗在消化系统相关疾病治疗中的疗效和安全性。
OBJECTIVE: To evaluate the efficacy and the safety of infliximab for the treatment of the diseases of digestive system.
我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
采用化学治疗药物(贝伐单抗，是中和血管内皮生长因子的人源化抗体)治疗可导致蛋白尿和肾功能损害。
Treatment with the chemotherapeutic agent bevacizumab, a humanized mab that neutralizes vascular endothelial growth factor, can lead to proteinuria and renal damage.
目的：探讨西妥昔单抗联合化疗治疗转移性结直肠癌的疗效和不良反应。
Objective: to determine the therapeutic effect and toxicity of cetuximab and chemotherapy agents in metastatic colorectal cancer.
目的：评估在局部进展期直肠癌患者中联合贝伐单抗和标准放化疗的新辅助治疗有效性和安全性，并探索标志物反应。
Purpose To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response.
目的研究PF 183单抗识别分子和胸腺细胞活化及凋亡的关系。
Objective to investigate the relationship between PF18 3 McAb recognized molecule and thymocyte activation induced apoptosis.
应用肿瘤相关糖蛋白72抗原(TAG - 72)的单抗72- 45及两种凝集素pna和dba对不同组织分型的大肠癌及癌旁组织进行了研究。
The 72 45 McAb of tumor associated glycoprotein (TAG) 72 antigen and two kinds of lectins PNA and DBA were expressed in large bowel carcinoma of different histologic patterns and transitional mucosa.
我们对已发表的随机、对照试验进行一项系统性回顾和荟萃分析，以评估应用贝伐单抗治疗引起重症蛋白尿的整体风险。
We performed a systematic review and meta-analysis of published randomized, controlled trials to assess the overall risk for severe proteinuria with bevacizumab.
目的研究抗细胞间黏附分子1 (ICAM 1)单抗对大鼠心肌缺血再灌注早期和远期死亡率及心功能的影响。
Objective To evaluate the effect of anti intercellular adhesion molecule 1 (ICAM 1) monoclonal antibody on cardiac function in rats with myocardial ischemia and different phase of reperfusion.
目的研究抗细胞间黏附分子1 (ICAM 1)单抗对大鼠心肌缺血再灌注早期和远期死亡率及心功能的影响。
Objective To evaluate the effect of anti intercellular adhesion molecule 1 (ICAM 1) monoclonal antibody on cardiac function in rats with myocardial ischemia and different phase of reperfusion.
应用推荐